B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels - Lazarus, Mark N.; Turner-Stokes, Tabitha; Chavele, Konstantia-Maria; Isenberg, David A.; Ehrenstein, Michael R. (Rheumatology (Oxford, England), 2012)
Keywords: Adolescent; Adult; Aged; Antibodies, Antinuclear - blood; Antibodies, Antinuclear - immunology; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antigens, CD20; B-Lymphocytes - immunology; B-Lymphocytes - metabolism; B-Lymphocytes - pathology; Biological and medical sciences; Child; Clinical Science; Diseases of the osteoarticular system; Endopeptidases - blood; Endopeptidases - immunology; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Immunity, Cellular; Immunologic Factors - therapeutic use; Immunomodulators; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - immunology; Lupus Erythematosus, Systemic - pathology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Phenotype; Rituximab; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Treatment Outcome; Young Adult; Antineoplastic agent; Human; Immunopathology; Connective tissue disease; Skin disease; Relapse; Antibody; CD20 antibody; Rheumatology; Rituximab; Autoimmune disease; B-Lymphocyte; anti-DNA antibodies; Immunomodulator; Phenotype; Systemic lupus erythematosus; Treatment; DNA; Systemic disease; β Cell; Immunosuppressive agent